Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): Pharmacological characterization and assessment in a rat model of cocaine dependence

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 4154-4172

  Dhanya, Raveendra Panickar ^a   Sheffler, Douglas J ^a   Dahl, Russell ^a   Davis, Melinda ^a   Lee, Pooi San ^a   Yang, Li ^a   Nickols, Hilary Highfield ^b,c   Cho, Hyekyung P ^b   Smith, Layton H ^a   D'Souza, Manoranjan S ^d   Conn, P Jeffrey ^b   Der Avakian, Andre ^d   Markou, Athina ^d   Cosford, Nicholas D P ^a  

^a BURNHAM INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 [4 [4 (2 CYCLOPENTYLACETYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY]BENZO ACID; 2 FLUORO 5 [4 (3 HYDROXY 2 METHYL 4 PROPIONYLPHENOXY)BUTOXY]BENZOIC ACID; 2 FLUORO 5 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOIC ACID; 3 [4 (4 BUTYRYL 3 HYDROXY 2 METHYLPHENOXY)BUTOXY] 4METHOXYBENZOIC ACID; 3 [4 [2,3 DIMETHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOIC ACID; 3 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY] 4 METHOXYBENZOIC ACID; 3 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY] 4 METHYLBENZOIC ACID; 3 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOIC ACID; 3 [4 [4 (2 CYCLOPENTYLACETYL) 2,3 DIMETHYLPHENOXY]BUTOXY]BENZOIC ACID; 3 [4 [4 (2 CYCLOPENTYLACETYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY]BENZOIC ACID; 3 [4 [4 (3,3 DIMETHYLBUTANOYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY] 2 METHYLBENZOIC ACID; 3 [4 [4 (3,3 DIMETHYLBUTANOYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY] 4 METHOXY BENZOIC ACID; 4 [4 [2,3 DIMETHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOIC ACID; 4 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY 3 METHOXYBENZOIC ACID; 4 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOIC ACID; 4 [4 [4 (2 CYCLOPENTYLACETYL) 2,3 DIMETHYLPHENOXY]BUTOXY]BENZOIC ACID; 4 [4 [4 (2 CYCLOPENTYLACETYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY]BENZOIC ACID; 4 [4 [4 (3,3 DIMETHYLBUTANOYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY] 5 METHOXYCYCLOHEXA 1,3 DIENECARBOXYLIC ACID; 5 [4 [2,3 DIMETHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY] 2 FLUOROBENZOIC ACID; 5 [4 [4 (2 CYCLOPENTYLACETYL) 2,3 DIMETHYLPHENOXY]BUTOXY] 2 FLUOROBENZOIC ACID; 5 [4 [4 (2 CYCLOPENTYLACETYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY] 2 FLUOROBENZOIC ACID; 5 [4 [4 (3,3 DIMETHYLBUTANOYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY] 2 FLUOROBENZOIC ACID; BENZOIC ACID DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; METABOTROPIC RECEPTOR AGONIST; METHYL 4 [4 [2,4 DIMETHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOATE; METHYL 4 [4 [3 HYDROXY 2 METHYL 4 (3 METHYLBUTANOYL)PHENOXY]BUTOXY]BENZOATE; METHYL 4 [4 [4 (2 CYCLOPENTYLACETYL) 2,3 DIMETHYLPHENOXY]BUTOXY]BENZOATE; METHYL 4 [4 [4 (2 CYCLOPENTYLACETYL) 3 HYDROXY 2 METHYLPHENOXY]BUTOXY]BENZOATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEPENDENCE TREATMENT; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELF ADMINISTRATION; DRUG SYNTHESIS; EMBRYO; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL STIMULATION; RAT; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; COCAINE-RELATED DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HEK293 CELLS; HUMANS; MALE; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84901269216     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5000563     Document Type: Article

References (58)

1. Marmiroli, P.; Cavaletti, G. The glutamatergic neurotransmission in the central nervous system Curr. Med. Chem. 2012, 19, 1269-1276
2. Sheffler, D. J.; Gregory, K. J.; Rook, J. M.; Conn, P. J. Allosteric modulation of metabotropic glutamate receptors Adv. Pharmacol. 2011, 62, 37-77
3. Conn, P. J.; Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237
4. Enz, R. Metabotropic glutamate receptors and interacting proteins: evolving drug targets Curr. Drug Targets 2012, 13, 145-156
5. Sheffler, D. J.; Pinkerton, A. B.; Dahl, R.; Markou, A.; Cosford, N. D. Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators ACS Chem. Neurosci. 2011, 2, 382-393
6. Cartmell, J.; Schoepp, D. D. Regulation of neurotransmitter release by metabotropic glutamate receptors J. Neurochem. 2000, 75, 889-907
7. Durand, D.; Carniglia, L.; Caruso, C.; Lasaga, M. mGlu3 receptor and astrocytes: partners in neuroprotection Neuropharmacology 2013, 66, 1-11
8. Corti, C.; Battaglia, G.; Molinaro, G.; Riozzi, B.; Pittaluga, A.; Corsi, M.; Mugnaini, M.; Nicoletti, F.; Bruno, V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection J. Neurosci. 2007, 27, 8297-8308
9. Ohishi, H.; Neki, A.; Mizuno, N. Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody Neurosci. Res. 1998, 30, 65-82
10. 3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain J. Pharmacol. Exp. Ther. 2001, 298, 453-460
11. Swanson, C. J.; Bures, M.; Johnson, M. P.; Linden, A. M.; Monn, J. A.; Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discovery 2005, 4, 131-144
12. Krystal, J. H.; Mathew, S. J.; D'Souza, D. C.; Garakani, A.; Gunduz-Bruce, H.; Charney, D. S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists CNS Drugs 2010, 24, 669-693
13. Chaki, S.; Ago, Y.; Palucha-Paniewiera, A.; Matrisciano, F.; Pilc, A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants Neuropharmacology 2013, 66, 40-52
14. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 2009, 30, 25-31
15. Sheffler, D. J.; Conn, P. J. Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia. In Glutamate-Based Therapies for Psychiatric Disorders; Skolnick, P., Ed.; Birkhäuser: Basel, Switzerland, 2010; pp 101-116.
16. Kenny, P. J.; Markou, A. The ups and downs of addiction: role of metabotropic glutamate receptors Trends Pharmacol. Sci. 2004, 25, 265-272
17. Xi, Z. X.; Ramamoorthy, S.; Baker, D. A.; Shen, H.; Samuvel, D. J.; Kalivas, P. W. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine J. Pharmacol. Exp. Ther. 2002, 303, 608-615
18. Adewale, A. S.; Platt, D. M.; Spealman, R. D. Pharmacological stimulation of group II metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys J. Pharmacol. Exp. Ther. 2006, 318, 922-931
19. Aujla, H.; Martin-Fardon, R.; Weiss, F. Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence Neuropsychopharmacology 2008, 33, 1818-1826
20. Baptista, M. A.; Martin-Fardon, R.; Weiss, F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer J. Neurosci. 2004, 24, 4723-4727
21. Peters, J.; Kalivas, P. W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats Psychopharmacology (Berlin, Ger.) 2006, 186, 143-149
22. Xi, Z. X.; Baker, D. A.; Shen, H.; Carson, D. S.; Kalivas, P. W. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens J. Pharmacol. Exp. Ther. 2002, 300, 162-171
23. Flor, P. J.; Battaglia, G.; Nicoletti, F.; Gasparini, F.; Bruno, V. Neuroprotective activity of metabotropic glutamate receptor ligands Adv. Exp. Med. Biol. 2002, 513, 197-223
24. Allen, J. W.; Ivanova, S. A.; Fan, L.; Espey, M. G.; Basile, A. S.; Faden, A. I. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury J. Pharmacol. Exp. Ther. 1999, 290, 112-120
25. Richards, G.; Messer, J.; Faull, R. L.; Stadler, H.; Wichmann, J.; Huguenin, P.; Bohrmann, B.; Mutel, V. Altered distribution of mGlu2 receptors in beta-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice Brain Res. 2010, 1363, 180-190
26. Ahnaou, A.; Dautzenberg, F. M.; Geys, H.; Imogai, H.; Gibelin, A.; Moechars, D.; Steckler, T.; Drinkenburg, W. H. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture Eur. J. Pharmacol. 2009, 603, 62-72
27. Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.; Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Tomlinson, R.; Lewis, R.; Griffey, K. R.; Tizzano, J. P.; Schoepp, D. D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2- aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors J. Med. Chem. 1999, 42, 1027-1040
28. Dominguez, C.; Prieto, L.; Valli, M. J.; Massey, S. M.; Bures, M.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D.; Monn, J. A. Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist J. Med. Chem. 2005, 48, 3605-3612
29. Hanna, L.; Ceolin, L.; Lucas, S.; Monn, J.; Johnson, B.; Collingridge, G.; Bortolotto, Z.; Lodge, D. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist Neuropharmacology 2013, 66, 114-121
30. Anwyl, R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity Brain Res. Rev. 1999, 29, 83-120
31. Cartmell, J.; Monn, J. A.; Schoepp, D. D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d -amphetamine motor behaviors in rats J. Pharmacol. Exp. Ther. 1999, 291, 161-170
32. Wieronska, J. M.; Stachowicz, K.; Branski, P.; Palucha-Poniewiera, A.; Pilc, A. On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice Neuropharmacology 2012, 62, 322-331
33. Galici, R.; Jones, C. K.; Hemstapat, K.; Nong, Y.; Echemendia, N. G.; Williams, L. C.; de Paulis, T.; Conn, P. J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice J. Pharmacol. Exp. Ther. 2006, 318, 173-185
34. Reiner, A.; Lafferty, D. C.; Wang, H. B.; Del Mar, N.; Deng, Y. P. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice Neurobiol. Dis. 2012, 47, 75-91
35. Reiner, A.; Wang, H. B.; Del Mar, N.; Sakata, K.; Yoo, W.; Deng, Y. P. BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice Brain Res. 2012, 1473, 161-172
36. Schiefer, J.; Sprunken, A.; Puls, C.; Luesse, H. G.; Milkereit, A.; Milkereit, E.; Johann, V.; Kosinski, C. M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease Brain Res. 2004, 1019, 246-254
37. Jin, X.; Semenova, S.; Yang, L.; Ardecky, R.; Sheffler, D. J.; Dahl, R.; Conn, P. J.; Cosford, N. D.; Markou, A. The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats Neuropsychopharmacology 2010, 35, 2021-2036
38. Bossert, J. M.; Poles, G. C.; Sheffler-Collins, S. I.; Ghitza, U. E. The mGluR2/3 agonist LY379268 attenuates context- and discrete cue-induced reinstatement of sucrose seeking but not sucrose self-administration in rats Behav. Brain Res. 2006, 173, 148-152
39. Cacciola, J.; Empfield, J.; Folmer, J.; Hunter, A. M.; Throner, S. Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286. U.S. Patent 7,790,760, September 7, 2010.
40. Pinkerton, A. B.; Cube, R. V.; Hutchinson, J. H.; Rowe, B. A.; Schaffhauser, H.; Zhao, X.; Daggett, L. P.; Vernier, J. M. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones Bioorg. Med. Chem. Lett. 2004, 14, 5329-5332
41. Pinkerton, A. B.; Cube, R. V.; Hutchinson, J. H.; James, J. K.; Gardner, M. F.; Rowe, B. A.; Schaffhauser, H.; Rodriguez, D. E.; Campbell, U. C.; Daggett, L. P.; Vernier, J. M. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators Bioorg. Med. Chem. Lett. 2005, 15, 1565-1571
42. Johnson, M. P.; Baez, M.; Jagdmann, G. E., Jr.; Britton, T. C.; Large, T. H.; Callagaro, D. O.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N -(4-(2-methoxyphenoxy)phenyl)- N -(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine J. Med. Chem. 2003, 46, 3189-3192
43. Pinkerton, A. B.; Vernier, J. M.; Schaffhauser, H.; Rowe, B. A.; Campbell, U. C.; Rodriguez, D. E.; Lorrain, D. S.; Baccei, C. S.; Daggett, L. P.; Bristow, L. J. Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor J. Med. Chem. 2004, 47, 4595-4599
44. Govek, S. P.; Bonnefous, C.; Hutchinson, J. H.; Kamenecka, T.; McQuiston, J.; Pracitto, R.; Zhao, L. X.; Gardner, M. F.; James, J. K.; Daggett, L. P.; Rowe, B. A.; Schaffhauser, H.; Bristow, L. J.; Campbell, U. C.; Rodriguez, D. E.; Vernier, J. M. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia Bioorg. Med. Chem. Lett. 2005, 15, 4068-4072
45. Duplantier, A. J.; Efremov, I.; Candler, J.; Doran, A. C.; Ganong, A. H.; Haas, J. A.; Hanks, A. N.; Kraus, K. G.; Lazzaro, J. T., Jr.; Lu, J.; Maklad, N.; McCarthy, S. A.; O'Sullivan, T. J.; Rogers, B. N.; Siuciak, J. A.; Spracklin, D. K.; Zhang, L. 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: hit-to lead and lead optimization Bioorg. Med. Chem. Lett. 2009, 19, 2524-2529
46. Tresadern, G.; Cid, J. M.; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; Garcia, A.; Matesanz, E.; Linares, M. L.; Oehlrich, D.; Lavreysen, H.; Biesmans, I.; Trabanco, A. A. Scaffold hopping from pyridones to imidazo[1,2- a ]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor Bioorg. Med. Chem. Lett. 2010, 20, 175-179
47. Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopoulos, A.; Conn, P. J.; Lindsley, C. W. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery J. Med. Chem. 2012, 55, 1445-1464
48. Dhanya, R. P.; Sidique, S.; Sheffler, D. J.; Nickols, H. H.; Herath, A.; Yang, L.; Dahl, R.; Ardecky, R.; Semenova, S.; Markou, A.; Conn, P. J.; Cosford, N. D. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats J. Med. Chem. 2011, 54, 342-353
49. Sidique, S.; Dhanya, R. P.; Sheffler, D. J.; Nickols, H. H.; Yang, L.; Dahl, R.; Mangravita-Novo, A.; Smith, L. H.; D'Souza, M. S.; Semenova, S.; Conn, P. J.; Markou, A.; Cosford, N. D. Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence J. Med. Chem. 2012, 55, 9434-9445
50. Schann, S.; Mayer, S.; Franchet, C.; Frauli, M.; Steinberg, E.; Thomas, M.; Baron, L.; Neuville, P. Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators J. Med. Chem. 2010, 53, 8775-8779
51. Cube, R. V.; Vernier, J. M.; Hutchinson, J. H.; Gardner, M. F.; James, J. K.; Rowe, B. A.; Schaffhauser, H.; Daggett, L.; Pinkerton, A. B. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl) propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2) Bioorg. Med. Chem. Lett. 2005, 15, 2389-2393
52. Fell, M. J.; Witkin, J. M.; Falcone, J. F.; Katner, J. S.; Perry, K. W.; Hart, J.; Rorick-Kehn, L.; Overshiner, C. D.; Rasmussen, K.; Chaney, S. F.; Benvenga, M. J.; Li, X.; Marlow, D. L.; Thompson, L. K.; Luecke, S. K.; Wafford, K. A.; Seidel, W. F.; Edgar, D. M.; Quets, A. T.; Felder, C. C.; Wang, X.; Heinz, B. A.; Nikolayev, A.; Kuo, M. S.; Mayhugh, D.; Khilevich, A.; Zhang, D.; Ebert, P. J.; Eckstein, J. A.; Ackermann, B. L.; Swanson, S. P.; Catlow, J. T.; Dean, R. A.; Jackson, K.; Tauscher-Wisniewski, S.; Marek, G. J.; Schkeryantz, J. M.; Svensson, K. A. N -(4-((2-(Trifluoromethyl)-3-hydroxy-4-(isobutyryl) phenoxy)methyl)benzyl)-1-methy l-1 H -imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes J. Pharmacol. Exp. Ther. 2011, 336, 165-177
53. Liechti, M. E.; Lhuillier, L.; Kaupmann, K.; Markou, A. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence J. Neurosci. 2007, 27, 9077-9085
54. Morishima, Y.; Miyakawa, T.; Furuyashiki, T.; Tanaka, Y.; Mizuma, H.; Nakanishi, S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 4170-4175
55. Niswender, C. M.; Johnson, K. A.; Luo, Q.; Ayala, J. E.; Kim, C.; Conn, P. J.; Weaver, C. D. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors Mol. Pharmacol. 2008, 73, 1213-1224
56. Hemstapat, K.; de Paulis, T.; Chen, Y.; Brady, A. E.; Grover, V. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators Mol. Pharmacol. 2006, 70, 616-626
57. Engers, D. W.; Niswender, C. M.; Weaver, C. D.; Jadhav, S.; Menon, U. N.; Zamorano, R.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs) J. Med. Chem. 2009, 52, 4115-4118
58. Sheffler, D. J.; Conn, P. J. Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia. In Glutamate-Based Therapies for Psychiatric Disorders; Skolnick, P., Ed.; Birkhäuser: Basel, Switzerland, 2010; pp 101-116.